ES2071227T3 - Composicion para gotas para los ojos. - Google Patents

Composicion para gotas para los ojos.

Info

Publication number
ES2071227T3
ES2071227T3 ES91307275T ES91307275T ES2071227T3 ES 2071227 T3 ES2071227 T3 ES 2071227T3 ES 91307275 T ES91307275 T ES 91307275T ES 91307275 T ES91307275 T ES 91307275T ES 2071227 T3 ES2071227 T3 ES 2071227T3
Authority
ES
Spain
Prior art keywords
composition
eye drops
benzoxadine
thioxo
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91307275T
Other languages
English (en)
Inventor
Kazumichi Ushio
Yoshifumi Ikejiri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2071227T3 publication Critical patent/ES2071227T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

SE DESCRIBE UNA COMPOSICION DE GOTAS PARA LOS OJOS QUE CONTIENEN COMO COMPONENTE PRINCIPAL EFECTIVO UN ACIDO 3, 4-DIHIDRO-2, 8-DIISOPROPIL3-TIOXO-2H-1, 4-BENZOXADINA-4-ACETICO O UNA SAL SUYA FARMACEUTICAMENTE ACEPTABLE Y CICLODEXTRINA.
ES91307275T 1990-08-13 1991-08-08 Composicion para gotas para los ojos. Expired - Lifetime ES2071227T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP21482790 1990-08-13
JP16285491 1991-07-03

Publications (1)

Publication Number Publication Date
ES2071227T3 true ES2071227T3 (es) 1995-06-16

Family

ID=26488494

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91307275T Expired - Lifetime ES2071227T3 (es) 1990-08-13 1991-08-08 Composicion para gotas para los ojos.

Country Status (16)

Country Link
US (1) US5663170A (es)
EP (1) EP0472327B1 (es)
JP (1) JP2769253B2 (es)
KR (1) KR920003971A (es)
AT (1) ATE121295T1 (es)
AU (1) AU633754B2 (es)
CA (1) CA2048942A1 (es)
DE (1) DE69109021T2 (es)
DK (1) DK0472327T3 (es)
ES (1) ES2071227T3 (es)
FI (1) FI97777C (es)
HU (1) HU207950B (es)
NO (1) NO177845C (es)
PT (1) PT98643B (es)
RU (1) RU2068260C1 (es)
TW (1) TW200402B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018764A2 (en) * 1992-03-18 1993-09-30 Coopervision Pharmaceuticals, Inc. VERAPAMIL HCl FORMULATION AND OTHER OPHTHALMIC SOLUTIONS WITH BUFFER SYSTEM FOR OCULAR ADMINISTRATION
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
WO1994010976A1 (en) * 1992-11-16 1994-05-26 Ciba Vision Ag, Hettlingen Polyvinyl alcohol/borate ophthalmic drug delivery system
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
EP0711147A1 (en) * 1993-07-28 1996-05-15 Insite Vision Incorporated Suspensions for delivery of medicament
US5977180A (en) * 1994-07-11 1999-11-02 Pate; David W. Anandamide analog compositions and method of treating intraocular hypertension using same
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
KR100261585B1 (ko) * 1995-01-20 2000-07-15 오쿠다 기요아키 항염증점안제
ATE215821T1 (de) * 1995-01-20 2002-04-15 Wakamoto Pharma Co Ltd Entzündungshemmende augentropfen
US6476004B1 (en) 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2002523475A (ja) * 1998-09-02 2002-07-30 アラーガン・セイルズ・インコーポレイテッド 防腐したシクロデキストリン含有組成物
JP2001125052A (ja) * 1999-10-25 2001-05-11 Lion Corp コンタクトレンズ装着液
ATE324910T1 (de) * 2000-06-19 2006-06-15 Santen Pharmaceutical Co Ltd Aseptische mittel
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
WO2006137433A1 (ja) * 2005-06-21 2006-12-28 Wakamoto Pharmaceutical Co., Ltd. レボカバスチンを可溶化させた水性薬剤
US20100069335A1 (en) * 2005-07-15 2010-03-18 Rajiv Bhushan Prevention and Treatment of Ophthalmic Complications of Diabetes
TR201820073T4 (tr) 2012-03-26 2019-01-21 Santen Pharmaceutical Co Ltd Diquafosol içeren göz damlası.
TW202014194A (zh) * 2018-04-27 2020-04-16 美商歐樂根公司 抗微生物功效增強且毒性降低之亞氯酸鈉組成物
KR102266014B1 (ko) * 2019-11-21 2021-06-17 삼진제약주식회사 안질환 예방 또는 치료용 점안 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU602641B2 (en) * 1986-04-17 1990-10-18 Senju Pharmaceutical Co., Ltd. Thiolactam-N-acetic acid derivatives, their production and use

Also Published As

Publication number Publication date
JPH05213757A (ja) 1993-08-24
PT98643A (pt) 1992-07-31
TW200402B (es) 1993-02-21
DK0472327T3 (da) 1995-05-08
US5663170A (en) 1997-09-02
FI97777B (fi) 1996-11-15
NO177845B (no) 1995-08-28
EP0472327B1 (en) 1995-04-19
KR920003971A (ko) 1992-03-27
FI97777C (fi) 1997-02-25
JP2769253B2 (ja) 1998-06-25
ATE121295T1 (de) 1995-05-15
PT98643B (pt) 1999-01-29
FI913811A (fi) 1992-02-14
DE69109021D1 (de) 1995-05-24
FI913811A0 (fi) 1991-08-12
EP0472327A1 (en) 1992-02-26
NO177845C (no) 1995-12-06
NO913136L (no) 1992-02-14
RU2068260C1 (ru) 1996-10-27
AU8170891A (en) 1992-02-20
CA2048942A1 (en) 1992-02-14
DE69109021T2 (de) 1995-09-21
NO913136D0 (no) 1991-08-12
HUT61196A (en) 1992-12-28
HU207950B (en) 1993-07-28
HU912692D0 (en) 1992-01-28
AU633754B2 (en) 1993-02-04

Similar Documents

Publication Publication Date Title
ES2071227T3 (es) Composicion para gotas para los ojos.
DE69010139D1 (de) Haarkräftigungsmittel.
ES2115733T3 (es) Composicion antialergica para uso oftalmico o nasal.
NO912630D0 (no) Fremgangsmaate for fremstilling av nye 2,6-dialkyl-4-silyl-fenoler.
ATE179173T1 (de) 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy 1,3-propandiol-derivate
DE69121211T2 (de) Applanationstonometer
FI911131A (fi) Menetelmä viherkaihia estävien 3-aryylikarbonyyli-1-aminoalkyyli-1H-indoliyhdisteiden valmistamiseksi
ES2127181T3 (es) 11-beta-aril-gona-4,9-dien-3-onas.
PT99503A (pt) Processo para a preparacao de novos derivados da n-benzoil-prolina e de composicoes farmaceuticas que os contem
BR9200627A (pt) Processo para a preparacao de um composto e composto obtido
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
DE69122555T2 (de) 2,4-Dihydroxyadipinsäurederivate
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
PT84750B (pt) Processo de preparacao de uma composicao para o envenenamento de roedores, a base de derivados de 1,4-naftoquinona
DK0775692T3 (da) Guanidinomethylcyclohexancarboxylsyreesterderivater
BR8801794A (pt) Composicao fungicida e processo para a preparacao de derivados de 2-(o-alquila/substituido/)-2-tio-1,3,2-oxatiofosfolano
DE3578172D1 (de) 2,5-pyrrolidindion-derivate mit antiarrhythmischer wirkung.
IT9021262A1 (it) Derivati 1, 4-benzotiacinici ad attivita' calcio antagonista
MX9203096A (es) Derivados de n-(2'-aminofenil)-benzamida, proceso para la preparacion de la misma y composiciones farmaceuticas que los contienen.
ES1014307Y (es) Pieza de ojete para calzados.
BR8902385A (pt) Politioureias,processo para a preparacao das mesmas
NO924046L (no) 2[, 3[-dideoksy-4[-tioribonukleosider som antivirusmidler

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 472327

Country of ref document: ES